Literature DB >> 19472184

p38 mitogen-activated protein kinase-dependent regulation of SRC-3 and involvement in retinoic acid receptor alpha signaling in embryonic cortical neurons.

Zhi Chai1, Lihong Yang, Baofeng Yu, Quanren He, Wan-I Li, Ran Zhou, Ting Zhang, Xiaoying Zheng, Jun Xie.   

Abstract

Appropriate retinoic acid (RA) signaling is essential in the development of the central nervous system (CNS). Previous studies have shown that RA activates p38 mitogen-activated protein kinase (MAPK) and steroid receptor coactivator (SRC)-3 in tumor cells in vitro. It is unknown whether the activation of p38 MAPK and SRC-3 is involved in RA-mediated CNS development. The current study investigated a possible role for p38 MAPK in the regulation of (SRC)-3 phosphorylation/degradation and in retinoic acid receptor (RAR)alpha signaling in mouse fetal cortical neurons treated with all-trans retinoic acid (ATRA). Results showed that ATRA treatment rapidly activated p38 MAPK, which in turn resulted in phosphorylation with subsequent degradation of SRC-3. Inhibition of p38 MAPK by SB203580 blocked the phosphorylation and degradation of SRC-3. The binding of RARalpha to retinoic acid responsive element (RARE) was rapidly increased in neurons following ATRA treatment. Inhibition of p38 MAPK significantly enhanced the RARalpha-RARE binding activity, but had no effects on ATRA-induced decrease of RARalpha. Treatment of the fetal cortical neurons with ATRA significantly increased the expression of HOXd3, a retinoid-target gene. The increase of HOXd3 expression was augmented when p38 MAPK activity was inhibited by a specific inhibitor, SB203580. Results suggest that ATRA activates the p38 MAPK signal pathway with resultant degradation of SRC-3, and that p38 MAPK is involved in the regulation of RARalpha-mediated signaling in developing neurons. (c) 2009 IUBMB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19472184     DOI: 10.1002/iub.212

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  4 in total

1.  Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.

Authors:  James W Antoon; Melyssa R Bratton; Lori M Guillot; Scott Wadsworth; Virgilio A Salvo; Matthew E Burow
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

2.  The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα.

Authors:  M Ying; L Zhang; Q Zhou; X Shao; J Cao; N Zhang; W Li; H Zhu; B Yang; Q He
Journal:  Oncogene       Date:  2016-01-18       Impact factor: 9.867

3.  Association of low-frequency and rare coding variants with information processing speed.

Authors:  Jan Bressler; Gail Davies; Albert V Smith; Yasaman Saba; Joshua C Bis; Xueqiu Jian; Caroline Hayward; Lisa Yanek; Jennifer A Smith; Saira S Mirza; Ruiqi Wang; Hieab H H Adams; Diane Becker; Eric Boerwinkle; Archie Campbell; Simon R Cox; Gudny Eiriksdottir; Chloe Fawns-Ritchie; Rebecca F Gottesman; Megan L Grove; Xiuqing Guo; Edith Hofer; Sharon L R Kardia; Maria J Knol; Marisa Koini; Oscar L Lopez; Riccardo E Marioni; Paul Nyquist; Alison Pattie; Ozren Polasek; David J Porteous; Igor Rudan; Claudia L Satizabal; Helena Schmidt; Reinhold Schmidt; Stephen Sidney; Jeannette Simino; Blair H Smith; Stephen T Turner; Sven J van der Lee; Erin B Ware; Rachel A Whitmer; Kristine Yaffe; Qiong Yang; Wei Zhao; Vilmundur Gudnason; Lenore J Launer; Annette L Fitzpatrick; Bruce M Psaty; Myriam Fornage; M Arfan Ikram; Cornelia M van Duijn; Sudha Seshadri; Thomas H Mosley; Ian J Deary
Journal:  Transl Psychiatry       Date:  2021-12-04       Impact factor: 6.222

4.  All-trans retinoic acid and human salivary histatin-1 promote the spreading and osteogenic activities of pre-osteoblasts in vitro.

Authors:  Wei Sun; Andi Shi; Dandan Ma; Jan G M Bolscher; Kamran Nazmi; Enno C I Veerman; Floris J Bikker; Haiyan Lin; Gang Wu
Journal:  FEBS Open Bio       Date:  2020-02-11       Impact factor: 2.693

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.